Plant-Based Protein Expression Coming of Age
Can plant-based protein expression systems turn into a leading industrial technology?
Dr John Butler-Ransohoff, Project Manager for Plant-made Pharmaceuticals, Bayer Innovations joined us at the World Vaccine Congress in Washington DC 2012 to answer this question. The advantages of plant- based expression include: speed, versatility and scalability, reduced cost of production, and in some cases, improved product quality.
The 2009 Flu pandemic showed us that transient plant-based expression may be best suited for pandemic vaccines. Producing countries use vaccines first and foremost to protect their own citizens, demonstrating the need for a “warm-base” production capacity with fast reaction times. The speed, versatility and scalability of plant-based expression could answer this need.
The most important aspect of vaccine production is safety. Plants derived proteins are safer in certain cases as plants do not harbour human pathogens, risking the risk from the production host. Reduced risk from vector is also possible as plant-viral vectors do not replicate in human tissue.
Why not download the full presentation to find out: Can plant cell-lines grow into the industry leaders?
• Why plant cell-lines are ideal for vaccine production and can address the problems of a pandemic
• Can the limiting factor of limited regulatory experience of plant cell-lines be overcome to allow the further developments?
• Understanding that the regulatory viral concerns surrounding plant cell-lines have less associated cost in DSP than mammalian cells